AGGF1 Antikörper

Produktnummer ABIN2192195

Der Kaninchen Polyklonal anti-AGGF1 Antikörper wird verwendet zum Nachweis von AGGF1 in Proben von Human. Er wurde validiert für WB, IP, IHC (p), IHC (fro) und IA.

Kurzübersicht für AGGF1 Antikörper (ABIN2192195)

Target: AGGF1 (Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AGGF1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoassay (IA)

Produktdetails anti-AGGF1 Antikörper

Sterilität: 0.2 μm filtered

Anwendungsinformationen

Applikationshinweise: For Western blotting and immunohistology dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.02 % sodium azide and 0.1 % bovine serum albumin.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Haltbarkeit: 12 months

Details zu AGGF1

Target: AGGF1 (Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))

Andere Bezeichnung: Vg5q

Hintergrund: The polyclonal antibody reacts with human VG5Q, a 84 kDa protein. VG5Q functions as an angiogenic factor in promoting angiogenesis and suppression of VG5Q expression inhibits vessel formation. Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. Angiogenesis has an essential role in pathological conditions such as cancer and various ischaemic and inflammatory diseases. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that the protein may act in an autocrine fashion. VG5Q interacts with TWEAK (also known as TNFSF12), another secreted angiogenic factor. VG5Q shows strong expression in blood vessels and is secreted when vessel formation is initiated. VG5Q protein was detected mostly in the cytoplasm and around the nuclei of human microvascular endothelial cells (HMVECs). Furthermore VG5Q is detected in human umbilical vein endothelial cells (HUVECs), human heart fibroblast (HHF) and ovarian cancer cells (OV-3), but low expression was detected in kidney cancer cells (RP-45), HeLa Cells and bladder cancer cells.